 |
Previous Article | Next Article 
The Journal of Neuroscience, October 15, 2000, 20(20):7798-7806
Persistent Alterations in Dendrites, Spines, and Dynorphinergic
Synapses in the Nucleus Accumbens Shell of Rats with
Neuroleptic-Induced Dyskinesias
Gloria E.
Meredith1, 4,
Ian E. J.
De Souza2, 5,
Thomas M.
Hyde3,
Geoffrey
Tipper4,
Mai Luen
Wong4, and
Michael F.
Egan3
1 Department of Basic Medical Science, University of
Missouri-Kansas City, School of Medicine, Kansas City,
Missouri 64108-2792, 2 Department of Zoology, Trinity
College, University of Dublin, Dublin, Ireland,
3 Clinical Brain Disorders Branch, National Institute of
Mental Health, Bethesda, Maryland 20892, 4 Department of
Anatomy, Royal College of Surgeons in Ireland, Dublin 2, Ireland, and
5 Department of Biological Sciences, Open University,
Milton Keynes, United Kingdom
 |
ABSTRACT |
Chronic treatment of humans or experimental animals with classical
neuroleptic drugs can lead to abnormal, tardive movements that persist
long after the drugs are withdrawn. A role in these neuroleptic-induced
dyskinesias may be played by a structural change in the shell of the
nucleus accumbens where the opioid peptide dynorphin is upregulated in
treated rats that show vacuous chewing movements (VCMs). The shell of
the nucleus accumbens normally contains a dense plexus of
dynorphinergic fibers especially in its caudomedial part. After 27 weeks of haloperidol administration and 18 weeks of withdrawal, the
immunoreactive labeling of this plexus is intensified when compared
with that after vehicle treatment. In addition, medium spiny neurons
here show a significant increase in spine density, dendritic branching,
and numbers of terminal segments. In the VCM-positive animals, the
dendritic surface area is reduced, and dynorphin-positive terminals
contact more spines and form more asymmetrical specializations than do
those in animals without the syndrome (VCM-negative and vehicle-treated
groups). Persistent, neuroleptic-induced oral dyskinesias could
therefore be caused by incontrovertible alterations, involving terminal remodeling or sprouting, to the synaptic connectivity of the accumbal shell.
Key words:
tardive dyskinesia; vacuous chewing movement; D1
receptor; D2 receptor; odds ratio; opioid peptide
 |
INTRODUCTION |
Tardive dyskinesia (TD) developed by
susceptible patients after chronic treatment with neuroleptic drugs can
persist for years after the drugs are stopped. This disorder is slow to
appear, and its pathophysiology is not well understood. Like humans,
some rats treated long-term with haloperidol develop vacuous chewing movements (VCMs), a syndrome that mimics both the time course and
symptoms of TD and thereby provides a good model of the disease (Egan
et al., 1996 ; Hashimoto et al., 1998 ).
There is speculation that TD is caused by excitotoxicity (De Keyser,
1991 ). Extracellular glutamate is elevated, and glutamate transport is
impaired in the striatum of long-term haloperidol-treated rats
(Yamamoto and Cooperman, 1994 ; De Souza et al., 1999 ). Chronic neuroleptic treatment in rats is associated with increased perforations in dorsal striatal synapses, but decreased glutamate immunolabeling (Meshul and Tan, 1994 ; Meshul et al., 1996 ). The density and size of
asymmetrical or symmetrical, dorsal striatal synapses are altered (Kerns et al., 1992 ; Roberts et al., 1995 ; Meshul et al., 1996 ; Mijnster et al., 1996 ), and spines or cells are reportedly lost from
the dorsal striatum in VCM-positive (+) animals (Pakkenberg et al.,
1973 ; Jeste et al., 1992 ; Kelley et al., 1997 ). Elevated levels of
glutamate could cause all these changes. However, some data are
conflicting, many alterations have been shown to occur independent of
the abnormal movements, and most changes fail to persist after the
drugs have been withdrawn.
In the nucleus accumbens in the ventral striatum, two territories, the
core and shell, are differentially connected and regulated by dopamine
(Deutch and Cameron, 1992 ; Zahm, 1992 ; Meredith et al., 1995 ). The
shell has been proposed as a site of antipsychotic action (Deutch et
al., 1992 ; Heimer et al., 1997 ), plays a role in feeding behavior and
abnormal oral movements (Fletcher and Starr, 1987 ; Koshikawa et al.,
1989 ; Deutch et al., 1992 ; Koene et al., 1993 ; Prinssen et al., 1994 ;
Cools et al., 1995 ; Kelley and Swanson, 1997 ; Stratford and Kelley,
1997 ), but has yet to be linked to neuroleptic-induced structural change.
Endogenous opioid peptides, which are particularly sensitive to
haloperidol treatment, are abundant in the ventral striatum (Meredith,
1999 ). Elevations in dynorphin mRNA in the accumbens have been
associated with high VCMs (Egan et al., 1994 , 1996 ). Dynorphin has also
been linked to structural damage and motor dysfunction elsewhere (Long
et al., 1988 ; Bakshi et al., 1990 ). Because the accumbal shell has a
rich dynorphinergic network (Van Bockstaele et al., 1995 ), the
question as to whether the dynorphin connections here are modified in
TD becomes significant. The goal of these studies therefore was to
examine, in a rat model of TD, how haloperidol affects the
morphological structure of accumbal shell neurons and their
dynorphinergic synaptic connections and whether structural changes
persist in VCM+ rats after the drugs have been withdrawn.
Parts of this paper have been published previously (Meredith et
al., 1997 ; De Souza et al., 2000 ).
 |
MATERIALS AND METHODS |
Ninety-seven male Sprague Dawley or Wistar rats, weighing 150 gm
at the start of the study, were housed two to a cage. Every 3 weeks for
a period of 27 or 30 weeks, 71 animals were injected with 28.5 mg/kg
haldol decanoate (equivalent of 1.0 mg/kg/day i.m.; McNeil
Pharmaceuticals), and 26 were injected with vehicle (VEH; sesame oil).
All rats were then kept for an additional 18-21 weeks during which
they were given no further injections. The presence or absence of VCMs
was monitored every 3 weeks before the injections. Rats were rated in a
random order in an uncovered 20 × 30 × 40 cm plastic cage
in front of a mirror. Each animal was unrestrained, and its vacuous
chewing movements were counted for 2 min by a rater who was blind to
the treatment. Two types of jaw movements were observed: (1) an
intermittent, isolated movement that was unrelated to grooming,
gnawing, or mouthing food was counted as one movement, and (2) bursts
of chewing, often associated with jaw tremors, usually consisted of two
to six VCMs in rapid succession. The bursts were counted and analyzed
separately but were not included in the data analysis. Tongue
protrusions were observed and were also not counted. Scores were
combined to assess the overall severity of the entire syndrome for each animal. Jaw movements were quantified over 14 rating sessions, and
groups were compared. The 10 haloperidol-injected animals with
the highest scores, and thus the most severe movements, during the
final five rating periods constituted the VCM+ group. Twelve drug-treated animals with the least movements made up the VCM-negative ( ) group. The remaining drug-treated animals were excluded from further analysis. Twelve VEH-treated animals were also selected at
random for the study. Statistical comparisons were made between the
selected groups (see Data analysis and statistics below).
After treatment and withdrawal periods, each animal was deeply
anesthetized with a mixture of ketamine (70 mg/kg) and xylazine (6 mg/kg) intraperitoneally and perfused briefly with Tyrode's solution
followed by fixative comprising 4.0% paraformaldehyde and 0.25%
glutaraldehyde dissolved in 0.1 M phosphate buffer, if the
brain tissue was to be used for ultrastructural study. Brains used for
dendritic analyses were perfused with 3% paraformaldehyde and 15%
saturated picric acid in 0.1 M phosphate buffer (Meredith et al., 1992 ). Ringer's and perfusion fluids were prepared as a single
batch for all animals in each part of the study, and timings for
administration of these fluids were kept uniform.
Electron microscopic preparation. After perfusion, each
brain was removed and blocked, and the forebrain was cut into sections at 70 µm. Sections to be viewed with the electron microscope (EM) were submitted to a "freeze-thaw" regimen (Meredith and
Arbuthnott, 1993 ) in which they were rinsed in an ascending series (5, 10, and 20%) of dimethylsulfoxide (DMSO) in phosphate (0.1 M) buffer, frozen in 20% DMSO solution, and allowed to
defrost at room temperature.
All sections were pretreated overnight in 10% normal goat serum (NGS),
rinsed, and incubated in rabbit anti-dynorphin A (Peninsula Laboratories), diluted 1:1000 in 0.05 M Tris-buffered
saline with 1% NGS added, for 72 hr at 4°C, followed by incubation
in biotinylated goat anti-rabbit IgG (1:200) for 9-12 hr at 4°C and
in avidin-biotin complex for 6 hr at 4°C. Incubation media for light
microscopic sections had 0.5% Triton X-100 added. Sections were
reacted for 20 min in 0.05% 3,3'-diaminobenzidine tetrahydrochloride
(DAB) with 0.01% H2O2 and,
if prepared for light microscopy, were mounted on slides from a 0.2%
gelatin solution, dehydrated, and coverslipped. Alternate sections,
prepared for the EM, were treated with 1% osmium tetroxide in
phosphate buffer for 30 min, dehydrated in ethanol, embedded in Epon
resin, and allowed to polymerize for 48 hr at 60°C on glass slides.
Uranyl acetate (1%) was added to the 70% alcohol step to increase
contrast in the EM. All sections were then examined and photographed
under the light microscope. Small blocks, cut from the cone area of the
caudomedial shell of the nucleus accumbens (Fig.
1), were mounted with fresh Epon onto
precured plastic blocks. Series of ultrathin sections were cut with a
Reichert OM-U4 ultramicrotome, mounted on slot grids, contrasted
with lead citrate, examined, and photographed in a Philips 301 EM. The
immunostaining of tissue prepared for the EM was primarily superficial,
because detergents were not used in the tissue preparation.
Immunolabeled terminals were photographed at magnifications up to
70,000× and analyzed for a variety of features. Sections incubated
without the primary antibodies showed no specific staining. The
specificity of the primary antiserum has been tested previously by the
use of immunoblots, and no significant cross-reactivity with enkephalin
was found (Van Bockstaele et al., 1995 ).

View larger version (18K):
[in this window]
[in a new window]
|
Figure 1.
Diagram of a coronal section through the rat
forebrain at a caudal level of the nucleus accumbens. Core and shell
territories of the nucleus are labeled as are the dorsomedial
(dm) and cone areas in the caudomedial shell.
CPU, Caudate-putamen.
|
|
Synaptic boutons were collected from 27 blocks prepared from the same
location in the nucleus accumbens (Fig. 1) for equal numbers of rats in
the three groups (three to five blocks per animal). Semiserial,
ultrathin sections (~90 nm in thickness) were collected from each
block and mounted onto grids. Because immunoreactive staining was very
superficial, sections were only collected through the most superficial
2 µm of each block. Each ultrathin section was scanned thoroughly in
the EM in the same manner, and all boutons that were immunoreactive and
contained identifiable vesicles were photographed. A total of 5187 dynorphin-immunoreactive boutons (between 400 and 500 boutons per
animal) were photographed initially. From these, only boutons that were
considered to be synaptic (as decided independently by two
investigators blind to the treatment) were accepted for analysis.
Boutons were counted as synaptic when parallel, distinctly thickened,
presynaptic and postsynaptic membranes were visible and separated by a
narrow cleft, and there was a minimum of three vesicles in the
immediate vicinity of the presynaptic membrane (Mijnster et al., 1996 ). If the postsynaptic membrane was at least three times the thickness of
the presynaptic side, the synapse was considered asymmetrical. Synaptic
thickenings that were discontinuous were judged to be perforated, even
though serial sections were not analyzed. Synaptic targets were
classified as somatic, if a clearly defined nucleus was present, or
spinous, if a spine apparatus was visible. Small structures lacking a
spine apparatus were identified as dendrites if their outer membrane
was complete; synaptic targets that were too disrupted or too small to
be identified were not included in the analysis. Bouton inclusions,
dense core vesicles (DCVs), and puncta adhaerens were noted.
Dendritic analysis. Six VCM+, eight VCM , and eight
VEH-treated animals were used for this part of the study. Each brain
was removed, and transverse slices 150 µm thick were cut (Fig. 1) and
coded so that the investigator was blind to the animal's treatment at
all times. Slices were counterstained with
4',6-diamidino-2-phenylindole (DAPI) at a concentration of
10 7 M for 10 min to reveal
neuronal somata. Each slice was viewed with a Nikon Optiphot 2UD
microscope equipped with extra long working distance objectives and
epifluorescence. A silver wire connected to a constant current source
(Digitimer U.K.) was placed in a 4% aqueous solution of biotinylated
Lucifer yellow (LY; Molecular Probes, Eugene, OR) in a glass pipette.
The pipette was visually guided into each DAPI-stained perikaryon by
the use of a motorized micromanipulator. A positive holding current of
1-5 nA was reversed after the pipette had impaled a cell, and LY was
released with a negative current of 1-3 nA over a period of 10 min.
Electrode resistance was maintained between 80 and 250 M (cf.
Meredith and Arbuthnott, 1993 ). After four to eight neurons were
intracellularly filled with LY, the slice was incubated in an
avidin-biotin complex for 90 min at room temperature and reacted
with 0.05% DAB and 1% ammonium nickel sulfate added.
Slices were then mounted onto glass slides from a 0.2% gelatin
solution, dehydrated, and coverslipped.
Labeled neurons were analyzed only if they could be unambiguously
assigned to the medial half of the shell of the nucleus accumbens and
if their dendritic trees were well filled and the spines were visible.
Morphometric analyses were performed by the use of a Nikon microscope
and a motorized stage coupled to hardware and software (Neurolucida;
Microbrightfield, Colchester, VT) dedicated to neuronal reconstruction.
A Sholl analysis of ring intersections (Sholl, 1981 ) was used to
estimate dendritic length. Spines were recorded with special markers,
and spine density was expressed as the mean number of spines per 10 µm for all segments >50 µm in length (Meredith et al., 1995 ). The
dendritic surface area was calculated by the use of the formula for the
surface area of a frustum of a cone:
where R1 is the radius at the
start of that segment portion, R2 is
the radius at the end of that portion, and h is the length. Branched and mushroom spines were also counted; the former had more
than one head clearly connected to a common shaft (Comery et al., 1996 ;
Robinson and Kolb, 1997 ), and the latter was so designated if the head
was >0.3 µm in diameter.
Data analysis and statistics. Behavioral ratings were used
to assess the effects of haloperidol treatment compared with VEH, the
incidence of the VCM syndrome and its persistence in a subset of
animals, and the effects of neuroleptic withdrawal on the VCM score.
These data were analyzed with a repeated measures ANOVA with one
between (groups of VCM+, VCM , and VEH) and one within (time) factor.
Post hoc comparisons of groups were conducted with Scheffe's t test.
The cross-sectional surface area and length of the active zones for all
dynorphin-immunoreactive synaptic boutons were measured and expressed
as a mean ± SEM. Values were pooled for respective animals
of each group, and all groups were compared by the use of a one-way
ANOVA. A Student's t test was used to compare two groups.
The largest synaptic terminals (those >1 SD of the mean area) were
compared separately by the use of ANOVA. Five synaptic variables were
rated as present or absent: (1) asymmetrical synaptic specialization,
(2) symmetrical synaptic specialization, (3) synaptic perforations of
each active zone, (4) dynorphin immunoreactivity in the target, and (5)
the structural nature of the synaptic target, i.e., spine, dendritic
shaft, soma, or other. These variables could not be studied with simple
parametric statistics or with unbiased stereology, because values were
independent of volume and recorded simply as present or absent. All
data summaries and statistical comparisons were performed blind to the
treatment. We elected to analyze the data by the use of odds ratios
(ORs), which predict the chances of an event occurring when a set
factor is present as compared with the odds of the event occurring in the absence of that factor. The Mann-Whitney U test was
used to assess differences between groups, and unmatched univariate ORs were calculated on two subanalyses of the data. For these unmatched analyses, p values were calculated by the use of the
two-tailed Fisher's Exact Test (for analyses with small numbers of
observations); ORs (95% confidence intervals) were computed by using
maximum likelihood procedures. Two comparisons of the values were made: (1) haloperidol treatment (VCM+ and VCM ) versus no treatment (VEH)
and (2) abnormal movement (VCM+) versus no abnormal movement (VCM and VEH).
To analyze dendritic and spine data, values were pooled for each group,
and a Kolmogorov-Smirnov test was used to assess the normality of the
distribution of each data set. Data sets not normally distributed were
compared by the use of a Kruskal-Wallis ANOVA followed by post
hoc nonparametric analysis with Mann-Whitney U tests.
Normal data sets were compared by the use of ANOVA followed by
post hoc Scheffe's tests or Student's t test,
as appropriate. Comparisons were also made between groups with respect
to dendritic branch order to ascertain the level of the dendritic
branch where morphological parameters were altered.
 |
RESULTS |
Behavioral measures of vacuous chewing
Both Wistar and Sprague Dawley rats were used in this study. The
behavioral data for these animals have been published previously (Egan
et al., 1996 ; De Souza, 2000 ). Briefly, the results of these studies
showed that over the 27-30 week treatment period, the haloperidol
groups showed a gradual increase in VCMs compared with the VEH-treated
group (treatment effect for Sprague Dawley rats, F = 45.4; df = 1; p = 0.0001; and for Wistar rats,
F = 9.378; df = 1; p = 0.0005;
treatment-by-time interaction for Sprague Dawley rats,
F = 3.7; df = 13; p = 0.0001; and
for Wistar rats, F = 9.496; df = 14;
p = 0.0001).
When the VCM ratings were compared between groups, there was, as
expected, a marked group effect for both strains
(p < 0.0007). The ratings for the VCM+ rats of
both strains slowly rose, because there was a group-by-time interaction
(p < 0.001). Mean ratings of the VCM+ group
during the last five sessions were significantly elevated compared with
those of the vehicle and VCM groups (Scheffe's t test,
VCM+ vs VEH, p = 0.0014; and VCM+ vs VCM ,
p = 0.003), whereas there was no difference between
VCM and VEH-treated groups for both strains. The VCM ratings did not
differ between strains; ~40% of the animals showed significantly
elevated VCMs throughout the treatment and withdrawal periods. However,
the persistence of VCMs was not as pronounced during the withdrawal
period for the Wistar strain as for the Sprague Dawley animals. In
agreement with the work of Tamminga et al. (1990) , VCM ratings for the
high-VCM group of Wistar rats began to fall toward control values at
the end of the withdrawal period, whereas that of the Sprague Dawley rats persisted at the same high level.
Dynorphin immunoreactivity
At the light microscopic level, dynorphin immunostaining was
heterogeneous in all animals, especially in the nucleus accumbens (Figs. 1, 2). It was seen primarily in
varicose fibers and puncta, but also in some cell bodies lying within
densely immunostained dynorphinergic plexuses (Fig. 2). At rostral
levels, small areas enriched with dynorphin-immunoreactive fibers and
varicosities were located dorsal and lateral to the anterior commissure
(see also Van Bockstaele et al., 1994 ). Further caudal in the shell, densely immunoreactive zones were found medially, and in the core, small intensely immunoreactive zones were visible lateral to and above
the anterior commissure (Fig. 2). Sections that were incubated without
the primary antiserum showed no specific immunoreactive staining.

View larger version (60K):
[in this window]
[in a new window]
|
Figure 2.
Light photomicrographs of sections through the
neostriatum and caudal nucleus accumbens. Each section has been
immunoreacted for dynorphin and is taken from a VEH-treated
(A), VCM (B), or VCM+
(C) rat. The caudomedial part of the shell of the
nucleus accumbens (boxed area) has been
enlarged in the inset of each micrograph. Note the
intense immunoreactivity and sharp borders of the cone and dm (Fig. 1)
areas of the shell in the VCM+ rat (C) as
compared with those of the VCM (B) and
VEH-treated (A) animals. Note the homogeneous
dynorphin immunoreactivity in the CPU. Asterisks mark
small dynorphin-positive areas in the lateral core and shell of the
nucleus. Note the increased immunoreactive intensity of these small
regions in the VCM+ (C) rat as compared with that
of the VCM (B) and VEH-treated
(A) animals. Scale bar: A, 500 µm (this scale bar is valid for B and C).
|
|
Distinctive differences between groups in the intensity, but not the
pattern, of dynorphin immunoreactivity were discernible (Fig. 2). The
greatest differences were found in the caudomedial shell, where the
cone area (Fig. 1) enriched with dynorphin immunoreactivity was capped
by a small, densely immunoreactive zone with a sharp border (dm; Figs.
1, 2, insets). The immunoreactive intensity gradually faded
further ventrally in the shell. In the VCM+ rats, the borders of the
cone and dm areas were more sharply delineated than were those seen in
the other two groups of animals (Fig. 2, compare C with
A,B). The cone (Fig. 1) was selected for ultrastructural analysis.
Dynorphin-immunoreactive synapses
In the EM, dynorphin-immunoreactive axons and dendrites, but
rarely somata, were found scattered in the tissue; immunolabeled terminals were also uncommon. All immunoreactive elements were characterized by the electron-dense DAB reaction product associated with vesicles (Fig.
3A-C,E,F). Nuclei of
dynorphin-positive perikarya were never immunostained, and
dynorphin-immunoreactive dendrites generally had spines. In total,
274 dynorphin-immunoreactive boutons were accepted as synaptic and were
distributed in approximately equal numbers over the three groups. These
synaptic terminals were filled with small clear vesicles (Fig.
3F) and primarily formed symmetrical contacts with
dendrites (Fig. 3B,F) (see also Van Bockstaele et
al., 1994 , 1995 ). In the VCM and VEH-treated groups,
dynorphin-positive terminals occasionally contacted perikarya (Fig.
3D,E), the latter of which always had a round nuclear
envelope characteristic of a medium spiny projection neuron (Fig.
3D). Dynorphin-immunoreactive terminals from all groups
had other features in common, such as dense core vesicles (Fig.
3C), which were characteristically located away from
terminal walls and the presynaptic specialization (Fig. 3C).
Bouton inclusions and multivesicular bodies (Fig. 3B) were associated with 3-4% of all terminals; puncta adhaerens
and vesicle-like, postsynaptic indentations were rare.

View larger version (163K):
[in this window]
[in a new window]
|
Figure 3.
Electron micrographs taken from the shell of the
nucleus accumbens in VCM+ (A-C), VCM
(D, E), and VEH-treated (F)
rats. A, The dynorphin-immunoreactive terminal contacts
two spines (arrows point to the active zone); one
contact (right side) is
perforated. B, A dynorphin-immunoreactive ending
forms a perforated, asymmetrical synapse (4 perforations labeled with
arrows) with a dendritic shaft
(dend). Note the multivesicular body
(mvb) within the terminal. C, A
dense core vesicle (dcv) is marked with a
white arrow. D, A
dynorphin-positive terminal (asterisk) makes a
symmetrical contact with the soma in a VCM rat. Note the round,
nonindented nuclear envelope, indicating that this is a medium spiny
neuron. E, terminal seen in D (asterisk).
F, A dynorphin-positive bouton makes a symmetrical
synaptic contact with a dendritic shaft in a VEH-treated animal. Scale
bars: A, 0.5 µm (valid for B, C, and
F); E, 0.1 µm; D, 2 µm. sp app, spine apparatus.
|
|
Most dynorphin-immunoreactive terminals formed a single synapse with
one postsynaptic target (Fig. 3B,E,F). Nevertheless, 12% of the dynorphin-positive terminals in VEH-treated brains and 8%
in VCM brains made synaptic contacts with two or three postsynaptic
targets; 21% of the terminals in VCM+ brains contacted more than one
target (Fig. 3A,C). Furthermore, in the VCM+ material, 15%
of the terminals that made multiple contacts formed more than three contacts.
The mean, cross-sectional area of dynorphin-immunoreactive terminals in
the VCM+ group was 13% larger than that in VEH-treated rats (Table
1), but the difference was not
significant. The largest (>1 SD above the mean) dynorphin-positive
terminals were found in the VCM+ animals, but these were not
significantly larger than those in the other two groups.
Dynorphin-immunolabeled endings of the VCM+ animals were more likely to
be perforated (Fig. 3A,C) and form multiple perforations
(Fig. 3B) than were those in the other groups; however the
difference was also not significant (Table 1). Dynorphin-positive
boutons in VCM+ rats contacted significantly fewer dynorphin-positive
targets [Table 1; odds ratio, 0.44; 95% confidence interval
(0.3-0.7)], formed significantly more asymmetrical specializations
[Table 1; odds ratio, 1.77; 95% confidence interval (0.3-0.9)], and
contacted significantly more spines [Table 1; odds ratio, 5.79; 95%
confidence interval (2.2-15.1)] and significantly fewer dendrites
[p = 0.02; odds ratio, 0.55; confidence interval
(1.1-2.9)]. Dynorphin-positive terminals contacted significantly more
dendrites in the VCM and VEH-treated groups than in the VCM+ group
[Table 1; odds ratio, 2.61; 95% confidence interval (1.5-4.5)].
Dendritic shafts and spines
Reconstructed neurons found in the caudomedial shell of
VEH-treated rats showed the typical configuration (Fig.
4). They had three to six proximal
dendritic segments, spine-free initial dendritic shafts, and densely
spiny distal segments (Fig. 4B). Morphometric analyses showed significant differences in spine density, tortuosity, and dendritic shaft surface area and volume between groups (compare Figs. 5A with B,C,
6). There was a 25% increase in the
spine density (p < 0.01) of neurons belonging
to VCM+ and VCM animals as compared with that of VEH-treated rats
(Figs. 5, 6; Table 1). Spines also appeared on the proximal dendritic
segments of VCM+ (Fig. 5C) and VCM rats. There was,
however, no change in the frequency of branched or mushroom-shaped
spines for any of the groups (ANOVA; F = 0.388 and
p = 0.687 for branched spines; F = 1.906 and p = 0.195 for mushroom-shaped spines).

View larger version (41K):
[in this window]
[in a new window]
|
Figure 4.
A, A typical neuron in the shell of
the nucleus accumbens filled with biotinylated LY and reacted with DAB
in a VEH-treated rat. Note the thickened, aspiny proximal dendritic
segments (arrows). B, A reconstruction of
the filled neuron pictured in A.
|
|

View larger version (13K):
[in this window]
[in a new window]
|
Figure 5.
Reconstructions of typical, medium spiny neurons
in the shell of the nucleus accumbens in a VEH-treated
(A), VCM (B), or VCM+
(C) rat. Note the tortuous distal dendritic
segments (small arrows) in
A and the straight segments in B
(asterisk) and in C. Note the higher
density of the spines in B and C as
compared with that in A and the spines on the proximal
dendritic segment (large arrow) in
C.
|
|

View larger version (24K):
[in this window]
[in a new window]
|
Figure 6.
Bar graphs illustrate the significant
differences between animal groups. Graphs show spine density
(left), tortuosity (middle), and
dendritic surface area (right) for VEH
(filled bar), VCM
(hatched bar), and VCM+
(open bar) animals. The
left and middle graphs show that spine
density is significantly (asterisks) increased and
tortuosity is significantly reduced for both VCM+ and VCM groups. The
right graph shows that dendritic segments in the VCM+
rats have significantly reduced surface areas as compared with those in
the other two groups.
|
|
Sholl (1981) analysis revealed a marked increase in branching, i.e.,
47% more branch points (p = 0.019) and 36%
more terminal segments (p = 0.025), in VCM+ and
VCM as compared with VEH-treated rats. The radial dendritic shaft
length increased by 25.4% (p = 0.058), and
neurons had more second (51%; p = 0.030)-, third (52%; p = 0.047)-, and fifth (234%; p = 0.029)-order dendritic segments for VCM+ and VCM rats than for
VEH-treated animals. Dendritic shafts of shell neurons in VEH-treated
brains were significantly more tortuous than were those seen in VCM+
and VCM material (p < 0.01; Figs. 5, 6). More
importantly, in VCM+ rats, dendritic segments were decreased in surface
area and volume (38% decrease; p = 0.03) when compared
with those in VEH-treated controls (Fig. 6). There were no significant
differences in dendritic volume or surface area between VCM and
VEH-treated rats (Fig. 6).
 |
DISCUSSION |
These results show an unambiguous structural response by neurons
in the shell of the nucleus accumbens to chronic haloperidol treatment.
They further provide compelling evidence of dramatic and persistent
changes in the dynorphinergic circuitry of the shell of the nucleus
accumbens that are associated with neuroleptic-induced dyskinesia. The
shifts in dynorphinergic synaptic contacts could be attributed to an
increase in axodendritic contacts in VCM and VEH-treated animals.
However, it more likely involves the remodeling and/or sprouting of
dynorphin-positive terminals in VCM+ rats (Fig.
7). Dynorphin mRNA is significantly
upregulated (Egan et al., 1994 ), and medium spiny neurons are
morphologically altered (present results) in the accumbal shell of
these animals. These data provide clear evidence that a structural
change in the dynorphinergic circuitry of the nucleus accumbens is
associated with the movement syndrome (Fig. 7).

View larger version (20K):
[in this window]
[in a new window]
|
Figure 7.
Schematic drawing of hypothetical changes that
dynorphin-immunoreactive terminals undergo in animals that are VCM+.
A, A sketch of a typical dendritic segment found in the
shell of the nucleus accumbens of a VEH-treated rat. Dynorphin-positive
endings (hatched) are shown contacting the dendritic
shaft, and glutamatergic boutons (filled) are
illustrated ending on spines. B, An illustration of a
dendritic segment from a VCM+ rat. After 18 weeks of withdrawal from 27 weeks of haloperidol treatment, this dendrite has increased spine
density and decreased surface area (see Fig. 6) when compared with that
of the VEH-treated animal seen in A. In response to
increased dynorphin production over the prolonged period,
dynorphin-positive (hatched) axodendritic synapses
change their shape and expand onto neighboring spines. Such growth
would permit the receptor-bearing membrane located in the spine
(Svingos et al., 1999 ) to come into close contact with a
vesicle-bearing terminal, presumably rendering it functional. These
dynorphinergic boutons would therefore form a new synapse on the spine,
with the appropriate specialization, i.e., asymmetrical. Furthermore,
new dynorphinergic terminals (dotted) may end on newly
formed spines after axonal sprouting. Glutamate endings
(solid) contact older spines. Regardless of the manner
in which new synapses are formed, such structural modifications in
dynorphin neurons and their synapses could alter the accumbal circuit
in a dramatic and enduring manner.
|
|
Technical considerations
The intensity of dynorphin immunoreactivity in VCM+ rats was
greater than that in other groups. Presumably this was not caused by
false-positive labeling, because antibody specificity has been established (Pickel et al., 1993 ), but rather by an increase in the
density of dynorphin-positive structures. Certainly, the light microscopic pattern of dynorphinergic elements did not differ between
the three groups or from that in previous reports (Van Bockstaele et
al., 1994 ). Furthermore, we controlled for variability in the fixation
and immunocytochemical procedures (Mijnster et al., 1996 ). Another
issue involves the use of odds ratios. Because there were multiple
observations made on each experimental animal, the data could not be
considered a simple random sample. Analyzing these data without taking
this into consideration would have resulted in biased estimates of
variance, leading to spuriously narrow confidence intervals. Therefore,
the odds ratio allowed the best estimate of the relationship between
the predictor variable and the outcome, and by adding the confidence
intervals, effects that occur in a small data set could be tested
(Altman et al., 1983 ; Gardner and Altman, 1986 ). Moreover, the
morphological events that were compared by the use of these ratios did
show clear increases or decreases in percentage terms.
Long-term neuroleptic treatment is accompanied by
synaptic modifications
Neuroleptic-induced oral dyskinesias are slow to develop both in
experimental animals and humans and can persist indefinitely after
cessation of drug treatment. Increased dopamine receptor binding has
long been discarded as a responsible factor, and there is growing
support for a structural basis (cf. Benes et al., 1985 ; Waddington,
1990 ; Mijnster et al., 1996 ). Ultrastructural studies have shown
increases in the size and perforations of dorsal striatal synapses
(Benes et al., 1985 ; Meshul and Casey, 1989 ; Roberts et al., 1995 ), but
no change (Benes et al., 1985 ), a rise (Uranova et al., 1991 ; Kerns et
al., 1992 ), or a decline (Roberts et al., 1995 ) in synaptic density in
the caudate-putamen of chronically treated rats. Changes that have been
reported consistently, such as increased perforations, seem to be
specific for glutamatergic endings, and although these can be
correlated with the development of VCMs (Meshul et al., 1994 , 1996 ),
they do not persist in VCM+ rats after drug withdrawal (Roberts et al.,
1995 ). Certainly, drug dosage and the means of administration could be
factors that influence these measures, but, more importantly, the
synaptic parameters or the region selected may not be appropriate for
the interpretation of the behavioral hypersensitivity.
Why the shell of nucleus accumbens?
The structural changes described here are found in the caudomedial
shell of the nucleus accumbens, a region densely innervated by
dopaminergic fibers from the ventral tegmental area (Voorn et al.,
1986 ; Brog et al., 1993 ). This part of the shell is contiguous with the
extended amygdala and important for mediating not only neuroleptic drug
actions but also the stress-induced sensitization of motor activity
(Alheid and Heimer, 1988 ; Deutch and Cameron, 1992 ; Deutch et al.,
1992 ; Kalivas et al., 1993 ). Shell circuits are involved in chewing,
induced either by dopaminergic agents or during feeding behavior
(Prinssen et al., 1994 ; Kelley and Swanson, 1997 ; Stratford and Kelley,
1997 ). The TD syndrome could therefore be attributed to this region,
particularly because these abnormal oral movements are exacerbated
during times of stress and anxiety (Tarsy, 1983 ).
The nucleus accumbens contains high levels of the dynorphin peptide and
its related receptors (Meredith, 1999 ; Meshul and McGinty, 2000 ). The
synthesis and release of this peptide are primarily regulated by
activity at dopamine D1 receptors (Gerfen et al., 1990 ), which are rich
in the shell of the nucleus accumbens (Bardo and Hammer, 1991 ). Chronic
haloperidol treatment is accompanied by elevations in dynorphin mRNA in
animals that develop tardive but not acute oral movements (Egan et al.,
1996 ). The elevated dynorphin message may be in response to other
changes brought about by haloperidol such as persistent endogenous
dopamine release that increases activity at the D1 receptor or
augmented levels of extracellular glutamate (Egan et al., 1991 ; See and
Chapman, 1994 ). Certainly, receptor stimulation inhibits striatal
glutamate release (Rawls and McGinty, 1998 ), suggesting that increased
dynorphin production is an effort to compensate for elevated glutamate.
Patch-clamp recordings from acutely dissociated cells have shown that
dynorphin reduces neuronal calcium currents and inhibits adenylate
cyclase activity (Gross et al., 1990 ). In a series of experiments that
examined immediate early gene induction by cocaine, Steiner and Gerfen
(1998) concluded that dynorphin can inhibit dopamine release and blunt
D1 receptor activation. This could occur via a negative feedback
mechanism involving receptors located presynaptically on dopamine
terminals (Svingos et al., 1999 ; Meshul and McGinty, 2000 ).
Remodeling of shell circuits underlies the
VCM syndrome
Dendritic surface area is an important parameter for synaptic
arrangements, because the number of synapses that are present on a
dendrite is proportional to the size of this feature (Harris and Kater,
1994 ). A decrease in surface area and the appearance of new spines
would therefore have serious consequences for synapse stability
(Halpain, 2000 ). Persistently elevated dynorphin (Egan et al., 1994 )
would ultimately require structural adaptations to accommodate the
increase in peptide production. Some of our previous work has shown
that subchronic haloperidol treatment alters the shape of striatal
opioid synapses (Mijnster et al., 1996 ). Thus, increased
dynorphin levels could lead to a change in the shape of existing
terminals, which would allow boutons to maneuver onto newly formed
spines and away from shrinking dendrites (Fig. 7). Because of these
results, it is surprising therefore that dynorphinergic boutons were
not significantly augmented in size in VCM+ rats. There could be
technical reasons for this. Dynorphinergic terminals are uncommon, and
serial sections were not collected because such an approach would have
produced too few data points for statistical analysis. Therefore, the
two-dimensional bouton areas recorded here may not have reflected the
full size range of terminals in each group. Nevertheless, the tissue
from VCM+ rats did contain the largest boutons and the greatest numbers of double or triple synapses of all the groups. Increased numbers of
double synapses have been correlated with haloperidol-induced behavioral hypersensitivity (Kerns et al., 1992 ). The numbers of DCVs
were also significantly increased for VCM+ rats as compared with those
in other groups (data not shown). DCVs store peptides, and an increase
in their numbers would signal a rise in dynorphin storage capacity (Van
Bockstaele et al., 1994 ).
Remodeling or sprouting of dynorphinergic terminals
New synapse formation or synaptogenesis is also likely for
dynorphinergic endings (Fig. 7), even though total striatal synaptic density may decrease in VCM+ animals (Roberts et al., 1995 ). A new
contact is not constrained in its synaptic specialization, and our
results show that increases in asymmetrical specializations could
reflect new synapse formation (Fig. 7), a possibility that has been
proposed in synaptic turnover models (Dyson and Jones, 1984 ). Neither
asymmetrical nor axospinous junctions are common for dynorphinergic
endings (Van Bockstaele et al., 1994 , 1995 ). There is evidence of
haloperidol-induced sprouting in the substantia nigra (Benes et al.,
1983 ), a region targeted mainly by dynorphinergic axons from the
striatum. Moreover, synaptophysin, a ubiquitous glycoprotein associated
with synaptic vesicles, is considered a direct measure of the presence
of mature synapses, and an upregulation of this protein or its mRNA
would indicate an increase in the absolute number of synapses
(Marquèze-Pouey et al., 1991 ). Recently, we found a significant
increase in synaptophysin mRNA after acute haloperidol administration
in the accumbal shell (E. Hamid, G. Meredith, and M. Egan, unpublished
observations), where axon collaterals of dynorphinergic neurons are
common. Such an early elevation in synaptophysin message may be a first
step in the sprouting process.
Significant reductions in the numbers of dynorphin-positive targets in
VCM+ rats can possibly be explained by the fact that DAB deposits are
not as obvious in spines as in other, larger structures (Pickel et al.,
1988 ) or that reduced dendritic volume means less antigen present for
immunolabeling. In early Huntington's disease, striatal dendrites
become longer and thinner before cell death (Ferrante et al., 1991 ). It
is possible that similar changes underlie the pathophysiology of this
neuroleptic-induced motor disorder. Clearly further work is needed to
elucidate the mechanisms fully.
 |
FOOTNOTES |
Received May 30, 2000; revised July 19, 2000; accepted July 27, 2000.
This research was supported by a grant from the Royal College of
Surgeons in Ireland Research Committee and an equipment grant from the
Health Research Board and the Wellcome Trust. We thank Drs. B. L. Roberts for helpful comments on this manuscript, J. Waddington for
advice on the behavioral measures, S. Giles for technical assistance,
and Ronan Conroy for his statistical help. The Media Services
Department at the Royal College of Surgeons in Ireland gave valuable
photographic assistance.
Correspondence should be addressed to Dr. G. E. Meredith,
Department of Basic Medical Science, University of Missouri-Kansas City, School of Medicine, 2411 Holmes Road, Kansas City, MO
64108-2792. E-mail: email:meredithg{at}umkc.edu.
 |
REFERENCES |
-
Alheid GF,
Heimer L
(1988)
New perspectives in basal forebrain organization of special relevance for neuropsychiatric disorders: the striatopallidal, amygdaloid and corticopetal components of the substantia innominata.
Neuroscience
27:1-39[Web of Science][Medline].
-
Altman DG,
Gore SM,
Gardner MJ,
Pocock SJ
(1983)
Statistical guidelines for contributors to medical journals.
Br Med J
286:1489-1493.
-
Bakshi R,
Newman AH,
Faden AI
(1990)
Dynorphin A-(1-17) induces alterations in free fatty acids, excitatory amino acids, and motor function through an opiate-receptor-mediated mechanism.
J Neurosci
10:3793-3800[Abstract].
-
Bardo MT,
Hammer Jr RP
(1991)
Autoradiographic localization of dopamine D1 and D2 receptors in the rat nucleus accumbens: resistance to differential rearing conditions.
Neuroscience
45:281-290[Web of Science][Medline].
-
Benes FM,
Paskevich PA,
Domesick VB
(1983)
Haloperidol-induced plasticity of axon terminals in rat substantia nigra.
Science
221:969-971[Abstract/Free Full Text].
-
Benes FM,
Paskevich PA,
Davidson J,
Domesick VB
(1985)
The effects of haloperidol on synaptic patterns in the rat striatum.
Brain Res
329:265-274[Web of Science][Medline].
-
Brog JS,
Salyapongse A,
Deutch AY,
Zahm D
(1993)
The patterns of afferent innervation of the core and shell in the "accumbens" part of the rat ventral striatum: immunohistochemical detection of retrogradely transported fluoro-gold.
J Comp Neurol
338:255-278[Web of Science][Medline].
-
Comery TA,
Stamoudis CX,
Irwin SA,
Greenough WT
(1996)
Increased density of multiple-head dendritic spines on medium-sized spiny neurons of the striatum in rats reared in a complex environment.
Neurobiol Learn Mem
66:93-96[Web of Science][Medline].
-
Cools AR,
Miwa Y,
Koshikawa N
(1995)
Role of dopamine D1 and D2 receptors in the nucleus accumbens in jaw movements of rats: a critical role of the shell.
Eur J Pharmacol
286:41-47[Web of Science][Medline].
-
De Keyser J
(1991)
Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia.
Clin Neuropharmacol
14:562-565[Web of Science][Medline].
-
De Souza IEJ
(2000)
Morphological change in nucleus accumbens as a basis for the development of haloperidol-induced movement disorders.
In: PhD thesis Trinity College, University of Dublin.
-
De Souza IEJ,
McBean GJ,
Meredith GE
(1999)
Chronic haloperidol treatment impairs glutamate transport in the rat striatum.
Eur J Pharmacol
382:139-142[Web of Science][Medline].
-
De Souza IEJ,
Dawson NM,
Meredith GE
(2000)
Modification of dendritic morphology in nucleus accumbens' shell and core neurons following chronic haloperidol treatment as a basis for the development of vacuous chewing movements.
Suppl Eur J Neurosci
12:135.
-
Deutch AY,
Cameron DS
(1992)
Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell.
Neuroscience
46:49-56[Web of Science][Medline].
-
Deutch AY,
Lee MC,
Iadarola MJ
(1992)
Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action.
Mol Cell Neurosci
3:332-341.
-
Dyson SE,
Jones DG
(1984)
Synaptic remodelling during development and maturation: junction differentiation and splitting as a mechanism for modifying connectivity.
Brain Res
315:125-137[Medline].
-
Egan MF,
Karoum F,
Wyatt RJ
(1991)
Effects of acute and chronic clozapine and haloperidol administration on 3-methoxy-tyramine accumulation in rat prefrontal cortex, nucleus accumbens, and striatum.
Eur J Pharmacol
199:191-199[Web of Science][Medline].
-
Egan MF,
Hurd Y,
Hyde TM,
Weinberger DR,
Wyatt RJ,
Kleinman JE
(1994)
Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias.
Synapse
18:178-189[Web of Science][Medline].
-
Egan MF,
Hurd Y,
Ferguson J,
Bachus SE,
Hamid EH,
Hyde TM
(1996)
Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol.
Psychopharmacology (Berl)
127:337-345[Medline].
-
Ferrante RJ,
Kowall NW,
Richardson EP
(1991)
Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry.
J Neurosci
11:3877-3887[Abstract].
-
Fletcher GH,
Starr MS
(1987)
Topography of dopamine behaviors mediated by D1 and D2 receptors revealed by intrastriatal injection of SJKF 38393, lisuride and apomorphine in rats with a unilateral 6-hydroxydopamine-induced lesion.
Neuroscience
20:589-597[Web of Science][Medline].
-
Gardner MJ,
Altman DG
(1986)
Confidence intervals rather than p values; estimation rather than hypothesis testing.
Br Med J
292:746-759.
-
Gerfen CR,
Engber TM,
Mahan LC,
Susel Z,
Chase TN,
Monsma Jr FJ,
Sibley DR
(1990)
D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.
Science
250:1429-1432[Abstract/Free Full Text].
-
Gross RA,
Moises HC,
Uhler MD,
MacDonald RL
(1990)
Dynorphin A and cAMP-dependent protein kinase independently regulate neuronal calcium currents.
Proc Natl Acad Sci USA
87:7025-7029[Abstract/Free Full Text].
-
Halpain S
(2000)
Actin and the agile spine: how and why do dendritic spines dance?
Trends Neurosci
23:141-146[Web of Science][Medline].
-
Harris KM,
Kater SB
(1994)
Dendritic spines: cellular specializations imparting both stability and flexibility to synaptic function.
Annu Rev Neurosci
17:341-371[Web of Science][Medline].
-
Hashimoto T,
Ross DE,
Gao X-M,
Medoff DR,
Tamminga CA
(1998)
Mixture in the distribution of haloperidol-induced oral dyskinesias in the rat supports an animal model of tardive dyskinesia.
Psychopharmacology (Berl)
137:107-112[Medline].
-
Heimer L,
Harlan RE,
Alheid GF,
Garcia MM,
De Olmos J
(1997)
Substantia innominata: a notion which impedes clinical-anatomical correlations in neuropsychiatric disorders.
Neuroscience
76:957-1006[Web of Science][Medline].
-
Jeste DV,
Lohr JB,
Manley M
(1992)
Study of neuropathologic changes in the striatum following 4, 8 and 12 months of treatment with fluphenazine in rats.
Psychopharmacology (Berl)
106:154-160[Medline].
-
Kalivas PW,
Churchill L,
Klitenick MA
(1993)
The circuitry mediating the translation of motivational stimuli into adaptive motor responses.
In: Limbic motor circuits and neuropsychiatry (Kalivas PW,
Barnes CD,
eds), pp 193-236. Boca Raton, FL: CRC.
-
Kelley AE,
Swanson CJ
(1997)
Feeding induced by blockade of AMPA and kainate receptors within the ventral striatum: a microinfusion mapping study.
Behav Brain Res
89:107-113[Web of Science][Medline].
-
Kelley JJ,
Gao XM,
Tamminga CA,
Roberts RC
(1997)
The effect of chronic haloperidol treatment on dendritic spines in the rat striatum.
Exp Neurol
146:471-478[Web of Science][Medline].
-
Kerns JM,
Sierens DK,
Kao LC,
Klawans HL,
Carvey PM
(1992)
Synaptic plasticity in the rat striatum following chronic haloperidol treatment.
Clin Neuropharmacol
15:488-500[Web of Science][Medline].
-
Koene P,
Prinssen EP,
Cools AR
(1993)
Involvement of the nucleus accumbens in oral behaviour in the freely moving rat.
Eur J Pharmacol
233:151-156[Web of Science][Medline].
-
Koshikawa N,
Aoki S,
Hiruta M,
Tomiyama K,
Kobayashi M,
Tsubio Y,
Iwata K,
Sumino R,
Stephenson JD
(1989)
Effects of intrastriatal injections of selective dopamine D-1 and D-2 agonists and antagonists on jaw movements of rats.
Eur J Pharmacol
163:227-236[Web of Science][Medline].
-
Long JB,
Petras JM,
Mobley WC,
Holaday JW
(1988)
Neurological dysfunction after injection of dynorphin A-(1-13) in the rat. II. Non-opioid mechanisms mediate loss of motor, sensory and autonomic function.
J Pharmacol Exp Ther
246:1167-1174[Abstract/Free Full Text].
-
Marquèze-Pouey B,
Wisden W,
Malosio ML,
Betz H
(1991)
Differential expression of synaptophysin and synaptoporin mRNAs in the postnatal rat central nervous system.
J Neurosci
11:3388-3397[Abstract].
-
Meredith G,
Egan MF,
Tipper G,
Wong ML,
Hyde T
(1997)
Ultrastructural changes in dynorphinergic terminals of nucleus accumbens in rats that display neuroleptic-induced vacuous chewing movements.
Soc Neurosci Abstr
23:399.
-
Meredith GE
(1999)
The synaptic framework for chemical signaling in nucleus accumbens.
In: Advancing from the ventral striatum to the extended amygdala: implications for neuropsychiatry and drug abuse (McGinty J,
ed), pp 140-156. New York: New York Academy of Sciences.
-
Meredith GE,
Arbuthnott GW
(1993)
The challenge of in vitro preparations for morphological investigations.
In: Morphological investigations of single neurons in vitro (Meredith GE,
Arbuthnott GW,
eds), pp 1-25. Chichester, UK: Wiley.
-
Meredith GE,
Agolia R,
Arts MPM,
Groenewegen HJ,
Zahm DS
(1992)
Morphological differences between projection neurons of the core and shell in the nucleus accumbens of the rat.
Neuroscience
50:149-162[Web of Science][Medline].
-
Meredith GE,
Ypma P,
Zahm DS
(1995)
The effects of dopamine depletion on the morphology of medium spiny neurons in the shell and core of the rat nucleus accumbens.
J Neurosci
15:3808-3820[Abstract].
-
Meshul CK,
Casey DE
(1989)
Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment.
Brain Res
489:338-346[Web of Science][Medline].
-
Meshul CK,
McGinty JF
(2000)
Kappa opioid receptor immunoreactivity in the nucleus accumbens and caudate-putamen is primarily associated with synaptic vesicles in axons.
Neuroscience
96:91-99[Web of Science][Medline].
-
Meshul CK,
Tan SE
(1994)
Haloperidol-induced morphological alterations are associated with changes in calcium/calmodulin kinase II activity and glutamate immunoreactivity.
Synapse
18:205-217[Web of Science][Medline].
-
Meshul CK,
Stallbaumer RK,
Taylor B,
Janowsky A
(1994)
Haloperidol-induced morphological changes in striatum are associated with glutamate synapses.
Brain Res
648:181-195[Web of Science][Medline].
-
Meshul CK,
Andreassen OA,
Allen C,
Jorgensen HA
(1996)
Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol.
Psychopharmacology (Berl)
125:238-247[Medline].
-
Mijnster MJ,
Ingham CA,
Meredith GE,
Docter GJ,
Arbuthnott GW
(1996)
Morphological changes in met5enkephalin-immunoreactive synaptic boutons in the rat neostriatum after haloperidol decanoate treatment.
Eur J Neurosci
8:716-726[Web of Science][Medline].
-
Pakkenberg H,
Fog R,
Nilkanthan B
(1973)
The long-term effect of perphenazine enathate on the rat brain: some metabolic and anatomical observations.
Psychopharmacologia
29:329-336.
-
Pickel VM,
Towle AC,
Joh TH,
Chan J
(1988)
Gamma-aminobutyric acid in the medial rat nucleus accumbens: ultrastructural localization in neurons receiving monosynaptic input from catecholaminergic afferents.
J Comp Neurol
272:1-14[Web of Science][Medline].
-
Pickel VM,
Chan J,
Sesack SR
(1993)
Cellular substrates for interactions between dynorphin terminals and dopamine dendrites in rat ventral tegmental area and substantia nigra.
Brain Res
602:275-289[Web of Science][Medline].
-
Prinssen EPM,
Balestra W,
Bemelmans FFJ,
Cools AR
(1994)
Evidence for a role of the shell of the nucleus accumbens in oral behaviour of freely moving rats.
J Neurosci
14:1555-1562[Abstract].
-
Rawls SM,
McGinty JF
(1998)
-Receptor activation attenuates L-trans-pyrrolidine-2,4-dicarboxylic acid-evoked glutamate levels in the striatum.
J Neurochem
70:626-634[Web of Science][Medline]. -
Roberts RC,
Gaither LA,
Gao X-M,
Kashyap SM,
Tamminga CA
(1995)
Ultrastructural correlates of haloperidol-induced oral dyskinesias in rat striatum.
Synapse
20:234-243[Web of Science][Medline].
-
Robinson TE,
Kolb B
(1997)
Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine.
J Neurosci
17:8491-8497[Abstract/Free Full Text].
-
See RE,
Chapman MA
(1994)
Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats.
Eur J Pharmacol
263:269-276[Web of Science][Medline].
-
Sholl DA
(1981)
In: The organization of the cerebral cortex. London: Methuen.
-
Steiner H,
Gerfen CR
(1998)
Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior.
Exp Brain Res
123:60-76[Web of Science][Medline].
-
Stratford TR,
Kelley AE
(1997)
GABA in the nucleus accumbens shell participates in the central regulation of feeding behavior.
J Neurosci
17:4434-4440[Abstract/Free Full Text].
-
Svingos AL,
Colago EEO,
Pickel VM
(1999)
Cellular sites for dynorphin activation of
-opioid receptors in the rat nucleus accumbens shell.
J Neurosci
19:1804-1813[Abstract/Free Full Text]. -
Tamminga CA,
Dale JM,
Goodman I,
Kaneda H,
Kaneda N
(1990)
Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains.
Psychopharmacology (Berl)
102:474-478[Medline].
-
Tarsy D
(1983)
Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis.
Clin Neuropharmacol
6:S9-S26.
-
Uranova NA,
Orlovskaya DD,
Apel K,
Klintsova AJ,
Haselhorst U,
Schenk H
(1991)
Morphometric study of synaptic patterns in the rat caudate nucleus and hippocampus under haloperidol treatment.
Synapse
7:253-259[Web of Science][Medline].
-
Van Bockstaele EJ,
Sesack SR,
Pickel VM
(1994)
Dynorphin-immunoreactive terminals in the rat nucleus accumbens: cellular sites for modulation of target neurons and interactions with catecholamine afferents.
J Comp Neurol
341:1-15[Web of Science][Medline].
-
Van Bockstaele EJ,
Gracy KN,
Pickel VM
(1995)
Dynorphin-immunoreactive neurons in the rat nucleus accumbens: ultrastructure and synaptic input from terminals containing substance P and/or dynorphin.
J Comp Neurol
351:117-133[Web of Science][Medline].
-
Voorn P,
Jorritsma-Byham B,
van Dijk C,
Buijs RM
(1986)
The dopaminergic innervation of the ventral striatum in the rat: a light and electron-microscopical study with antibodies against dopamine.
J Comp Neurol
251:84-99[Web of Science][Medline].
-
Waddington JL
(1990)
Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia.
Psychopharmacology (Berl)
101:431-447[Medline].
-
Yamamoto BK,
Cooperman MA
(1994)
Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations.
J Neurosci
14:4159-4166[Abstract].
-
Zahm DS
(1992)
An electron microscopic morphometric comparison of tyrosine hydroxylase-immunoreactive innervation in the neostriatum and nucleus accumbens core and shell.
Brain Res
575:751-756.
Copyright © 2000 Society for Neuroscience 0270-6474/00/20207798-09$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
X.-M. Ma, D. D. Kiraly, E. D. Gaier, Y. Wang, E.-J. Kim, E. S. Levine, B. A. Eipper, and R. E. Mains
Kalirin-7 Is Required for Synaptic Structure and Function
J. Neurosci.,
November 19, 2008;
28(47):
12368 - 12382.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Hekmat-Scafe, K. N. Dang, and M. A. Tanouye
Seizure Suppression by Gain-of-Function escargot Mutations
Genetics,
March 1, 2005;
169(3):
1477 - 1493.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|